Meeting
2016 Genitourinary Cancers Symposium
Early toxicity in a randomized trial of high dose-rate (HDR) brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.
Authors
Gerard Morton
Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
Gerard Morton , Hans T. Chung , Merrylee McGuffin , Liying Zhang , Ananth Ravi , Laura D'Alimonte , Andrew Loblaw
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Clinical Trial Registration Number
NCT01890096
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 44)
DOI
10.1200/jco.2016.34.2_suppl.44
Abstract #
44
Poster Bd #
C4
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
5-Year result of single-institute cohort study in single-fraction HDR monotherapy for localised prostate cancer.
First Author: Imtiaz Ahmed
Poster
2020 Genitourinary Cancers Symposium
Stereotactic body radiotherapy boost toxicity for high and intermediate-risk prostate cancer: Report of a multi-institutional study.
First Author: Irving D. Kaplan
Poster
2019 Genitourinary Cancers Symposium
Rectal toxicity results for patients treated with HDR brachytherapy as monotherapy versus dose-escalated external beam radiotherapy for localized prostate cancer.
First Author: Jacob Samuel Parzen
Poster
2017 Genitourinary Cancers Symposium
Early toxicity in a prospective phase I/II trial of MRI-assisted focal boost integrated with HDR monotherapy for low- and intermediate-risk prostate cancer.
First Author: Laura D'alimonte